ArticleJournal of biomedical science2022

Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.

Yongsheng Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.